OBJECTIVES: A new concept of Patient-Reported Outcome (PRO) on quality indicators for pharmaceutical services is presented. It aims to supplement postmarketing surveillance tools. It is based on research findings from a patient survey instrument designed at Harvard and applied to a Primary Care Group in Warwickshire, as a quality improvement tool (Value in Health, vol 5, issue 3, 2002).  AHRQ considers the indicators for the Clearing House and the measures could complement indicators on clinical quality of providers from the NIH Promis initiative in the United States (or the NHS Proms in the UK). METHODS: The concept development is relevant for chronic care.  Five domains represent outpatient drug care: information, communication access, trust and clinical quality. Four process measures and one access measure are proposed with series of 5 -7 items,  tested on pharmacy delivery systems and dispensing doctors.The trust indicator has been identified as critical for the US drug delivery system and discussed as an example.  RESULTS: Trust adresses the potential patient mistrust when cost interfere with clinical judgement. The process measure is calculated for prescribing and treatment decisions for Hypertension, Diabetes and Asthma.It is a rate base  measure . The Facct scoring method is modified to integrate minima in low score values. Mean scores are calculated on samples per practice. Missing values are replaced by mean value. The evidence  from the UK PCT on a scale of 0-100, for three practices show scores of 66.78; 63.82;73.92  and 67.72 for the whole sample with a Cronbach of 0.70. CONCLUSIONS:  A composite indicator is envisaged for diffferent decision points in clinical practices. It is to be linked to clinical decision points from the Adaptive Knowledge Platform (AKP)  (Huttin, Liebamn, 2011) on breast cancer and could fit the requirements for the 12 rules for EGD in cancer. Validations in additional organisations of care and delivery systems are planned in further validation stages.